Another departure: Gilead’s cancer exec leaves

The executive vice president of oncology therapeutics at Gilead Sciences will leave the company to pursue another opportunity, the company announced this week.

Advertisement

Alessandro Riva, MD, joins a long list of leadership departures from Gilead. The company also saw its CEO John Milligan, Chairman John Martin, R&D chief Norbert Bischofberger and CMO Andrew Cheng exit the company.

Dr. Riva is shifting to lead a new biotech spinoff from India’s Glenmark, which will be based in the U.S. The spinoff will focus on oncology and T-cell therapies, according to EndPoints News.  

Dr. Riva joined Gilead in January 2017 and will remain with the company until the end of March.

More articles on pharmacy:
Viewpoint: It’s time for pharma to have its ‘tobacco moment’
Novartis to pay $23M to settle claims it used charity payments as kickbacks
Drugmakers are treating patients, providers ‘like piggy banks,’ AHA chief says

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.